ILA.AU Island Pharmaceuticals Ltd

Healthcare Biotechnology Australian Securities Exchange
0.2900 AUD
Close of Nov 1, 2026
0.2600 0.6300
Market cap
AUD 85.8M
P/E
-
P/B
6.38x
ROE
-149.6%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ILA.AU undervalued?

Graham number

The Graham number of Island Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Island Pharmaceuticals Ltd fundamental analysis

4 of 21 checks passed

ROE 0/2

Low return on equity (-149.6%), below 10%.

ROA 0/1

Return on assets (-143.8%) is below the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-61.0%) is below the industry median (-5.3%).

Revenue Growth 2/2

Revenue grew 194.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (6.4x) is above the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Island Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Island Pharmaceuticals Ltd

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Isla…

Full company profile